Patents by Inventor Kwong-yok Tsang

Kwong-yok Tsang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20230331797
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: June 29, 2023
    Publication date: October 19, 2023
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
    Patent number: 11732017
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: August 22, 2023
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Development of agonist epitopes of the human papillomavirus
    Patent number: 11311613
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: April 26, 2022
    Assignee: The United States of Americans represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
    Patent number: 11155588
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: October 26, 2021
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20210253656
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: April 26, 2021
    Publication date: August 19, 2021
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 11065318
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: July 20, 2021
    Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20200109181
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 9, 2020
    Applicant: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
    Patent number: 10508141
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: December 17, 2019
    Assignee: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • DEVELOPMENT OF AGONIST EPITOPES OF THE HUMAN PAPILLOMAVIRUS
    Publication number: 20190314479
    Abstract: The invention provides HPV agonist epitopes, which can be used as a peptide, polypeptide (protein), and/or in a vaccine or other composition for the prevention or therapy of HPV infection and/or cancer. The invention further provides a nucleic acid encoding the peptide or polypeptide (protein), a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide (protein), nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: November 6, 2017
    Publication date: October 17, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF
    Publication number: 20190231859
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Application
    Filed: December 6, 2018
    Publication date: August 1, 2019
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 10188714
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: January 29, 2019
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20190002513
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: July 13, 2018
    Publication date: January 3, 2019
    Applicant: The USA, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Native and agonist CTL epitopes of the MUC1 tumor antigen
    Patent number: 10138271
    Abstract: The invention provides peptides comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) mucin 1 (MUC1) and analogs thereof, which can be used in vaccine prevention or therapy of cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: November 27, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
    Patent number: 10035832
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: July 31, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • YEAST-MUC1 IMMUNOTHERAPEUTIC COMPOSITIONS AND USES THEREOF
    Publication number: 20170224794
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Application
    Filed: November 22, 2016
    Publication date: August 10, 2017
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • Yeast-MUC1 immunotherapeutic compositions and uses thereof
    Patent number: 9533031
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising mucin-1 (MUC1), as well as methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of mucin-1 (MUC1).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 3, 2017
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Alex Franzusoff, Zhimin Guo, Jeffrey Schlom, Kwong-Yok Tsang
  • HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
    Publication number: 20160251406
    Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.
    Type: Application
    Filed: October 22, 2014
    Publication date: September 1, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV
    Inventors: Jeffrey SCHLOM, Kwong-Yok TSANG
  • Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
    Patent number: 9370559
    Abstract: Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: June 21, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Heath Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang
  • Immunogenic peptides and methods of use
    Patent number: 9175057
    Abstract: The PAGE4 gene is expressed in reproductive tissues, and is expressed in reproductive cancers, such as prostate cancer, uterine cancer, and testicular cancer. Immunogenic PAGE4 polypeptides are disclosed herein, as are nucleic acids encoding the immunogenic PAGE4 polypeptides, vectors including these polynucleotides, and host cells transformed with these vectors. These polypeptides, polynucleotides, vectors, and host cells can be used to induce an immune response to PAGE4. Diagnostic methods to detect PAGE4 are also described.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: November 3, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang, Ira H. Pastan
  • Human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1
    Patent number: 8957192
    Abstract: Novel MUC-1 epitopes outside the VNTR region are identified. In addition, the first agonist epitope of MUC-1 is described. The employment of agonist epitopes in peptide, protein and vector-based vaccine may well aid in the development of effective vaccines for a range of human cancers.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: February 17, 2015
    Assignee: The United States of America, as represented by the Secretary Department of Health and Human Services
    Inventors: Jeffrey Schlom, Kwong-Yok Tsang